Cancer prevalence in France: Time trend, situation in 2002 and extrapolation to 2012

Colonna, Marc; Danzon, Arlette; Delafosse, Patricia; Mitton, N.; Bara, Simona; Bouvier, Anne–Marie; Ganry, O.; Guizard, Anne‐Valérie; Launoy, Guy; Molinié, F.; Sauleau, Erik-André; Schvartz, Claire; Velten, Michel; Grosclaude, Pascale; Trétarre, Brigitte

doi:10.1016/j.ejca.2007.10.022

Cited by 65 publications

(48 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There were 679,000 new cases of prostate cancer worldwide in 2002 (1) with 40,000 new cases being reported in France in 2000 (2,3). The incidence of prostate cancer has increased 4-fold during the last two decades, and in the US, one in eight men will develop prostate cancer during his lifetime (4).…”

Section: Introductionmentioning

confidence: 99%

BRCA1, BRCA2, AR and IGF-I expression in prostate cancer: Correlation between RT-qPCR and immunohistochemical detection

Rabiau

Déchelotte²,

Adjakly³

et al. 2011

Oncol Rep

View full text Add to dashboard Cite

Abstract. Identification and characterization of biomarkers in prostate cancer are important for improving the diagnosis. The aim of this study was to determine differences in the expression of 4 genes according to the stage of malignancy in prostate cancer. We analyzed BRCA1, BRCA2, androgen receptor (AR) and IGF-I gene expression in a cohort of 98 prostate biopsies. We used TaqMan RT-qPCR for mRNA detection, and correlation with proteins was performed using immunohistochemistry. Among the 98 studied prostate biopsies, high heterogeneity in the expression of the 4 genes was detected among the different histological types. However, down-regulation of BRCA1 and BRCA2 mRNA was detected, particularly in the normal tissues. The expression of AR was dependent on the stage of the tumor. The IGF-I gene was specifically expressed in the tumor tissues. Upon comparison between protein and mRNA expression for BRCA1, BRCA2 and AR, we obtained a trend; however, this did not achieve statistical significance. Regarding IGF-I, a correlation between mRNA expression and staining intensity of the protein was found to be significant (p<0.012). The AR biomarker was found to be slightly correlated with the prostate cancer diagnosis (p=0.013). AR was found to be decreased in the tumors with a 43% sensitivity and 90% specificity. The relative risk of 2.05 (1.13-3.69) indicated a 2-fold higher chance of cancer occurence when AR was ≤0.206.

show abstract

Section: Introductionmentioning

confidence: 99%

BRCA1, BRCA2, AR and IGF-I expression in prostate cancer: Correlation between RT-qPCR and immunohistochemical detection

Rabiau

Déchelotte²,

Adjakly³

et al. 2011

Oncol Rep

View full text Add to dashboard Cite

show abstract

“…5 Use of different periods and/or populations may have influenced the differences between prevalence rates among different authors. 2,[4][5][6][7][8] In the future, it is possible that there may be reductions in breast cancer prevalence in some parts of the world, due to greater primary prevention of breast cancer, including bilateral prophylactic mastectomy [34][35][36] and chemoprevention through the …”

Section: Discussionmentioning

confidence: 99%

“…North America and Europe contribute the highest rates (125.9/100,000 and 106.2/100,000 respectively). 3 Other studies 2,[4][5][6][7][8] have also shown increased prevalence rates.…”

Section: Introductionmentioning

confidence: 99%

“…These increases have been correlated with higher incidence and longer survival 2,[7][8][9] and with population screening programs, thereby giving rise to higher case prevalence, especially of cases detected in the initial stages. 10 Such increases made breast cancer the malignant neoplasia of highest prevalence in the year 2002, with 17.9% of the cancer cases worldwide (4.4 million).…”

Section: Introductionmentioning

confidence: 99%

“…1,2 They describe the number of people living with the disease of interest in a particular location or over a certain period. However, with regard to cancer, the definition of prevalence is unclear, since it is difficult to determine what is meant when it is said that an individual has been "cured".…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Prevalence of breast cancer in the city of Goiânia, Goiás, Brazil, between 1988 and 2002

et al. 2011

View full text Add to dashboard Cite

CONTEXT AND OBJECTIVE: Studies have shown increased prevalence rates for breast cancer, relating to higher incidence, longer survival and breast cancer prevention programs among populations. The aim here was to analyze the annual prevalence of breast cancer in Goiânia over a 15-year period. DESIGN AND SETTING: This was a cross-sectional study on women with breast cancer diagnosed in Goiânia, Goiás, Brazil, from 1988 to 2002. METHODS: The breast cancer cases were identified in the database of the Population-Based Cancer Registry of Goiânia. The 15-year period was stratified into three five-year periods. The cases were followed up for five years, and the mortality database was used to exclude deaths. The population of the official census was used as the denominator for rate calculations. RESULTS: The coefficient of breast cancer prevalence in Goiania was 22.87/100,000 in 1988 and 220.22/100,000 women in 2002. The analyses for periods showed that in the first period, the rate was 19.39/100,000 and that it was 44.79/100,000 in the last period. For the fifteen years analyzed, the prevalence rate for breast cancer was 127.24/100,000 women. The annual percentage change was 27.07 (P < 0.001; 95% confidence interval, CI: 20.79-33.67) from 1988 to 1992 and 9.39 (P < 0.001; 95% CI: 8.52-10.25) from 1992 to 2002. CONCLUSION: There was an increase in the breast cancer prevalence rate in the city of Goiânia between 1988 and 2002, possibly relating to the improvement in the screening and treatment of breast cancer

show abstract

Prevalence and Clinical Significance of Anti–Laminin 332 Autoantibodies Detected by a Novel Enzyme-Linked Immunosorbent Assay in Mucous Membrane Pemphigoid

Bernard

Antonicelli²,

Bédane³

et al. 2013

JAMA Dermatol

View full text Add to dashboard Cite

Importance:A rare variant of mucous membrane pemphigoid (MMP) is characterized by circulating antilaminin 332 (Lam332) autoantibodies and seems to be associated with concurrent malignant neoplasms.Objective: To determine the prevalence and clinical significance of anti-Lam332 autoantibody detection from a large series of patients with MMP.Design: Multicenter retrospective study. Interventions: Serum samples were analyzed by a new Lam332 enzyme-linked immunosorbent assay (ELISA); clinical and immunopathologic data were obtained from the patients' medical records. Main Outcome Measures:The Lam332 ELISA scores were evaluated with respect to clinical characteristics, standard and salt-split indirect immunofluorescence, and bullous pemphigoid (BP) 230 and BP180-NC16A ELISAs.Results: The Lam332 ELISA score was positive (Ն9 U/mL) in 20.1% of serum samples from patients with MMP, 1 of 50 patients with bullous pemphigoid (BP), none of 7 with pemphigus, and 3 of 32 other controls. No relationship was evidenced between a positive ELISA Lam332 score and age; sex ratio; oral, ocular, genital, skin, or esophageal/laryngeal involvement; internal malignant neoplasm; or BP180 ELISA score. Salt-split skin indirect immunofluorescence and ELISA BP230 results were more frequently positive when Lam332 ELISA results were positive (P=.04 and .02, respectively). Patients with a positive Lam332 ELISA score frequently had more severe MMP (67.8% vs 47.2%; P=.04). Conclusions and Relevance:Results of this novel ELISA showed that serum anti-Lam332 autoantibodies are detected in 20.1% of patients with MMP. AntiLam332 autoantibodies are mainly detected in patients with severe MMP but not preferentially in those with a malignant neoplasm. The association between antiLam332 and anti-BP230 autoantibodies might arise from an epitope-spreading phenomenon.

show abstract

Cancer prevalence in France: Time trend, situation in 2002 and extrapolation to 2012

Cited by 65 publications

References 10 publications

BRCA1, BRCA2, AR and IGF-I expression in prostate cancer: Correlation between RT-qPCR and immunohistochemical detection

BRCA1, BRCA2, AR and IGF-I expression in prostate cancer: Correlation between RT-qPCR and immunohistochemical detection

Prevalence of breast cancer in the city of Goiânia, Goiás, Brazil, between 1988 and 2002

Prevalence and Clinical Significance of Anti–Laminin 332 Autoantibodies Detected by a Novel Enzyme-Linked Immunosorbent Assay in Mucous Membrane Pemphigoid

Contact Info

Product

Resources

About